# Diabetes Research Hub — Monitor Review

**Run date:** 2026-08-13 (automated, unattended)
**Scope:** Read-only review of latest script outputs. No files modified.

---

## Headline: the data-collection pipeline stalled on 2026-07-17

The single most actionable finding this run is not in the data — it's the *age* of the data. The two baseline collectors and the file monitor stopped producing output 27 days ago, while a subset of downstream scripts kept running. Everything below is read from a frozen 2026-07-17 snapshot.

| File | Last updated | Age | Status |
|------|-------------|-----|--------|
| `clinical_trials_latest.json` | 2026-07-17 | 27 days | **STALE** |
| `pubmed_recent_latest.json` | 2026-07-17 | 27 days | **STALE** |
| `hub_monitor_report.md` | 2026-07-17 | 27 days | **STALE** |
| `literature_gap_data.json` | 2026-07-18 | 25 days | **STALE** |
| `literature_gap_report.md` | 2026-08-12 | 0 days | Fresh |
| `agent_state.json` | 2026-08-12 | 0 days | Fresh |
| `citation_validation.json` | 2026-08-12 | 0 days | Fresh |
| Latest trial/PubMed snapshot | `*_2026-07-17.json` | 27 days | **STALE** |

**Interpretation:** `agent_state.json`, `citation_validation.json`, and `literature_gap_report.md` are current, so the daily agent loop and the gap/citation steps are still firing. But `baseline_clinical_trials.py`, `baseline_pubmed_alerts.py`, and `hub_monitor.py` have not written new output since 2026-07-17. The nightly snapshot series (`clinical_trials_snapshot_*`, `pubmed_recent_snapshot_*`) also ends 2026-07-17. That points to a break in the data-ingestion half of the pipeline specifically — not a total outage.

> ⚠️ Because the underlying data is frozen, the trial and PubMed findings below reflect the state as of **2026-07-17**, not today. Treat them as a re-review of the last live snapshot, not new intelligence. Confidence: **[Certain]** on staleness (file timestamps); **[Likely]** on the cause being the two collector scripts plus hub_monitor.

---

## Clinical Trial Changes

Compared the last live snapshot (2026-07-17) against one month prior (2026-06-17) to summarize the final month of live data.

**Totals:** 813 → 858 tracked trials (+62 new, −17 removed). Category mix at 2026-07-17: T1D Cure & Cell Therapy 152, T1D Immunotherapy & Prevention 76, T2D Novel Therapies 147, Diabetes Technology 236, Recently Completed w/ Results 321.

**New Phase 3 RECRUITING trials in that window (6):**

- `NCT07662044`, `NCT07662109`, `NCT07662135`, `NCT07662213` — **AstraZeneca**, elecoglipron Phase III program (T2D)
- `NCT07670416` — **Hoffmann-La Roche**, enicepatide (RO7795068)
- `NCT07675499` — **Rutgers**, exercise + intranasal insulin in T2D

**Key Phase 3 trials from watched sponsors (current status as of 2026-07-17):**

- **Vertex** `NCT06832410` & `NCT04786262` — VX-880 (zimislecel), T1D islet cell therapy — **RECRUITING**. This is the flagship T1D cure program; regulatory submission is expected in 2026 (see Breaking News).
- **Eli Lilly** `NCT07222332` & `NCT07222137` — baricitinib for beta-cell preservation / Stage 3 T1D delay — **RECRUITING**.
- **Novo Nordisk** `NCT07564414` — CagriSema — **RECRUITING**; `NCT07076199` — insulin icodec — **RECRUITING**.
- **Sanofi** `NCT07088068` — teplizumab vs placebo — **RECRUITING**.

**Notable status changes in the window (12 total), highlights:**

- `NCT01897688` — islet transplant Phase 3 → **COMPLETED**
- `NCT06111586` — frexalimab (beta-cell preservation) RECRUITING → ACTIVE_NOT_RECRUITING
- `NCT05594563` — polyamines in T1D RECRUITING → ACTIVE_NOT_RECRUITING
- `NCT05866536` / `NCT05180591` — repeat BCG vaccination trials RECRUITING → ACTIVE_NOT_RECRUITING

**Data caveat:** `has_results` is `false` for all 858 records and `results_posted` is empty across the file, even though a 321-trial "Recently Completed with Results" category exists. The results-parsing field looks like it is not being populated — worth checking in `baseline_clinical_trials.py`. Confidence: **[Certain]** the field is empty; **[Guessing]** on cause.

---

## PubMed Highlights (as of 2026-07-17 snapshot)

158 unique papers across 16 domains, 30-day lookback.

**Cross-domain papers (12 — highest value).** Selected:

- `[42459945]` Algorithmic discrimination risks in pediatric T1D training data — **AI/ML × Closed Loop AP × Health Equity** (3 domains; maps directly to Tier 1 equity + AI).
- `[42419792]` Comparative effects of obesity drugs (systematic review) — **orforglipron × retatrutide × CagriSema**.
- `[42437645]` Variant-specific pharmacophoric shifts in GLP-1 receptor — **GLP-1 Pharmacogenomics × orforglipron**.
- `[42453334]` Noncoding RNAs for diabetes (in silico → clinic) — **Biomarker × LADA**.
- `[42459212]` / `[42458730]` Precision nutrition / multi-omic BMI modelling — **Microbiome × Multi-Omics** (maps to Tier 1 multi-omics).

**Key-therapy tracking (30-day counts):** dapagliflozin 52, orforglipron 10, CagriSema 6, retatrutide 4, teplizumab 4, icodec 3, baricitinib 2, **zimislecel 0**.

- **Flag:** zimislecel returned **0 hits** despite being Vertex's headline T1D asset with positive ADA data. Likely a query-term issue (papers may index under "VX-880," "stem cell-derived islets," or "islet cell therapy"). Recommend adding aliases to the PubMed alert query. Confidence: **[Likely]**.

**Volume note:** total unique papers 158 vs. ~28 new/day churn in the last live diff — consistent with a healthy 30-day window at the time of capture. No anomalous spikes or dead domains in the frozen data.

---

## Gap Analysis Summary

`literature_gap_report.md` reran 2026-08-12 (fresh), querying PubMed live for domain counts through 2026/07/17. 30 domains, 435 pairs. **Validation level: BRONZE** (single analytical source; requires expert confirmation per Research Doctrine).

**Top under-researched intersections (Gap Score / joint pubs):**

1. Treg / CAR-T × Neuropathy — 100.0 / 0
2. Beta Cell Regen × Health Equity — 100.0 / 0
3. Treg / CAR-T × Health Equity — 100.0 / 0
4. Glucokinase × Health Equity — 100.0 / 0
5. Gene Therapy × LADA — 100.0 / 0
6. Drug Repurposing × Health Equity — 100.0 / 0
7. Insulin Resistance × Islet Transplant — 91.9 / 1

**Alignment with Tier 1 contribution areas (RESEARCH_DOCTRINE.md):** Four of the top seven gaps route through **Health Equity** (Tier 1 #6, Epidemiological/Disparity Analysis) and one through **Drug Repurposing** (Tier 1 #4). The Beta Cell Regen × Health Equity and Drug Repurposing × Health Equity gaps sit squarely inside two Tier 1 lanes at once — these are the strongest "we have the tools and the gap is real" candidates. Multi-omics gaps (Microbiome × Multi-Omics cross-domain papers above) map to Tier 1 #1. Caveat: all gap scores are BRONZE and keyword-based; verify each with a direct combined-term PubMed search before committing analyst time.

---

## Breaking News (web check, last 7 days)

**Nothing genuinely new this week.** The significant 2026 developments are all already in the pipeline and predate the 7-day window:

- **Retatrutide** — first Phase 3 T2D+obesity results (ADA, June 2026): HbA1c −1.7 to −1.9% vs −0.8% placebo; weight −11.5 to −15.3%. Already tracked.
- **Orforglipron** — ACHIEVE Phase 3 program presented at ADA 2026; 52-week head-to-head beat oral semaglutide (HbA1c −1.71 to −1.91% vs −1.47%). Already tracked.
- **Zimislecel (VX-880)** — positive Phase 1/2 data at ADA 2026 (all 12 full-dose patients engrafted; ≥1 insulin-independent); **regulatory submission expected in 2026** — watch item.
- **Garzulys (insulin aspart-fsan)** — FDA-approved 2026-07-24 (NovoLog biosimilar). Outside the 7-day window; no action.

No FDA action, Phase 3 readout, or major publication in the trailing 7 days meets the "flag it" bar.

Sources: [ADA — Triple-Hormone Therapy](https://diabetes.org/newsroom/press-releases/breakthrough-studies-demonstrate-effectiveness-first-triple-hormone-therapy) · [ADA 2026 highlights (DiabetesontheNet)](https://diabetesonthenet.com/diabetes-primary-care/ada-2026/) · [Vertex — Zimislecel data](https://news.vrtx.com/news-releases/news-release-details/vertex-presents-positive-data-zimislecel-type-1-diabetes) · [Orforglipron NEJM](https://www.nejm.org/doi/abs/10.1056/NEJMoa2505669) · [FDA generic dapagliflozin](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets)

---

## Recommended Actions

**Priority 1 — restart the stalled data pipeline (data is 27 days old):**

- Run: `python baseline_clinical_trials.py` — refresh trial snapshot (last: 2026-07-17)
- Run: `python baseline_pubmed_alerts.py` — refresh PubMed alerts (last: 2026-07-17)
- Run: `python hub_monitor.py` — regenerate file-change report (last: 2026-07-17)
- Then check *why* they stopped on 2026-07-17 (cron/scheduler, API key, rate limit, or a crash). The fact that `agent_state.json` and gap/citation steps kept updating suggests the scheduler runs but these three scripts fail — check their logs first.

**Priority 2 — fix two data-quality bugs surfaced this run:**

- Add zimislecel aliases ("VX-880", "stem cell-derived islet", "hypoimmune islet") to the PubMed key-therapy query — currently returns 0 hits for a flagship asset.
- Investigate empty `has_results` / `results_posted` fields in `clinical_trials_latest.json` (all 858 records blank despite a 321-trial "with results" category).

**Priority 3 — analyst follow-ups (once data is fresh):**

- Verify the two double-Tier-1 gaps with direct PubMed combined-term searches before committing time: **Beta Cell Regen × Health Equity** and **Drug Repurposing × Health Equity**.
- Review cross-domain paper `[42459945]` (algorithmic discrimination in pediatric T1D) — hits Tier 1 AI/ML + Health Equity.
- Track zimislecel/VX-880 for the expected 2026 regulatory submission; Vertex trials `NCT06832410` and `NCT04786262` remain RECRUITING.

**No action needed:** breaking-news scan (nothing new in 7 days); gap report itself (reran fresh 2026-08-12).

---
*Read-only review run. Findings on trials/PubMed reflect the frozen 2026-07-17 snapshot. Evidence levels noted inline per Research Doctrine v1.0.*
